Therapeutic keratopigmentation Vis-à-Vis in blind eyes: complications and outcomes in a series of 184 eyes

盲眼患者接受治疗性角膜色素沉着术的疗效比较:184例眼部病例的并发症和结果

阅读:1

Abstract

PURPOSE: To evaluate the outcomes, complications, and patient satisfaction following therapeutic keratopigmentation Vis-à-Vis in blind eyes. METHODS: This retrospective case series included 184 eyes from blind patients who underwent KTP between 2016 and 2024, using either inorganic or mixed pigments. Superficial automated, superficial manual, and intrastromal manual approaches were performed according to corneal indication. Data collected comprised demographic information, surgical techniques, pigment type, postoperative complications, re-epithelialization time, and long-term stability. Patient-reported outcomes regarding cosmetic satisfaction and quality-of-life impact were also assessed. RESULTS: The overall median re-epithelialization time was 14 days, though delayed healing occurred in < 20% of the patients. Postoperative complications included pigment fading, infectious keratitis, photophobia and corneal melting, though most were manageable and did not compromise final cosmetic outcomes. Cases of MRI-related ocular discomfort were noted in eyes pigmented with iron oxide-based compounds but resolved without structural alterations. At final follow-up, cosmetic appearance was graded as good to excellent in 90% of cases, and 88% of patients expressed high satisfaction, reporting improved psychosocial wellbeing. CONCLUSION: Therapeutic keratopigmentation Vis-à-Vis emerges as a meaningful intervention for blind eyes, not merely restoring external harmony but also restoring dignity and quality of life. Even with a tangible risk of complications, long-term pigment stability and high satisfaction rates highlight its value as both a reconstructive and humanizing procedure in corneal surgery.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。